Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines

Vaccine

Volumn 29, Issue 18, 2011, Pages 3390-3397

  Westdijk, Janny ^a   Brugmans, Debbie ^a   Martin, Javier ^b   Oever, Aart van't ^a   Bakker, Wilfried A M ^a   Levels, Lonneke ^c   Kersten, Gideon ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Antigenicity; Immunogenicity; Inactivated polio vaccine; Sabin

Indexed keywords

NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG POTENCY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTYPE; VIRUS NEUTRALIZATION; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; POLIOVIRUS; POLIOVIRUS VACCINES; RATS; REFERENCE STANDARDS;

EID: 79954880585     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.085     Document Type: Article

References (29)

1. Dowdle W.R., Featherstone D.A., Birmingham M.E., Hull H.F., Aylward R.B. Poliomyelitis eradication. Virus Res 1999, 62(August (2)):185-192.
2. WHO, World Health Organisation Global polio eradication initiative strategic plan 2004-2008 2003, World Health Organisation, Geneva, Switzerland, p. 1-40.
3. Sutter R.W., Caceres V.M., Mas Lago P. The role of routine polio immunization in the post-certification era. Bull World Health Organ 2004, 82(January (1)):31-39.
4. WHO, World Health Organisation WHO global action plan for laboratory containment of wild poliovirus 2003, World Health Organisation, Geneva, Switzerland. 2nd ed.
5. Kersten G., Hazendonk T., Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 1999, 17(April (15/16)):2059-2066.
6. Simizu B., Abe S., Yamamoto H., Tano Y., Ota Y., Miyazawa M., et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006, 34(June (2)):151-154.
7. Doi Y., Abe S., Yamamoto H., Horie H., Ohyama H., Satoh K., et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001, 105:163-169.
8. Dragunsky E.M., Ivanov A.P., Wells V.R., Ivshina A.V., Rezapkin G.V., Abe S., et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004, 190(October (8)):1404-1412.
9. Wood D.J., Heath A.B., Sawyer L.A. A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals 1995, 23(March (1)):83-94.
10. Wood D.J., Heath A.B. A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Biologicals 1995, 23(December (4)):301-311.
11. Wood D.J., Heath A.B., Kersten G.F., Hazendonk T., Lantinga M., Beuvery E.C. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine. Biologicals 1997, 25(March (1)):59-64.
12. van Wezel A.L., van Steenis G., Hannik C.A., Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand 1978, 41:159-168.
13. van Wezel A.L., van Herwaarden J.A., van de Heuvel-de Rijk E.W. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines. Dev Biol Stand 1979, 42:65-69.
14. WHO, World Health Organisation. Requirements for poliomyelitis vaccine (inactivated). World Health Organ Tech Rep Series; 2002, Annex 2:910:32e65.
15. Kersten G.F., Lantinga M., Hazendonk T., Beuvery E.C. Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats. Biologicals 1995, 23(June (2)):179-183.
16. Koch F., Koch G. The molecular biology of poliovirus 1985, Springer Verlag, Wien, NY.
17. van Steenis G., van Wezel A.L., Sekhuis V.M. Potency testing of killed polio vaccine in rats. Dev Biol Stand 1981, 47:119-128.
18. Albrecht P., van Steenis G., van Wezel A.L., Salk J. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984, 6(May-June (Suppl. 2)):S540-S544.
19. Dernick R. Antigenic structure of poliovirus. Dev Biol Stand 1980, 47:319-333.
20. Heukeshoven J., Dernick R. Chemische analyse und struktur des poliovirus. I. Cystein/cystin gehalt, vollständige Aminosäureanalyse und Hydrophobizität von Poliovirus und seinen natürlichen leeren Kapsiden. Z Naturforsch 1981, 36:164-172.
21. Dragunsky E.M., Ivanov A.P., Wells V.R., Ivshina A.V., Rezapkin G.V., Abe S., et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004, 190(8):1404-1412.
22. Sigmundsson K., Masson G., Rice R., Beauchemin N., Obrink B. Determination of active concentrations and association and dissociation rate constants of interacting biomolecules: an analytical solution to the theory for kinetic and mass transport limitations in biosensor technology and its experimental verification. Biochemistry 2002, 41(July (26)):8263-8276.
23. Swartz T.A., Handsher R., Stoeckel P., Drucker J., Caudrelier P., Van Wezel A.L., et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989, 5(June (2)):143-145.
24. Linder N., Handsher R., German B., Sirota L., Bachman M., Zinger S., et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed 2000, 83(July (1)):F24-F27.
25. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(August (3)):401-409.
26. Rezapkin G., Martin J., Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 2005, 33(1):29-39.
27. Tano Y., Shimizu H., Martin J., Nishimura Y., Simizu B., Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007, 25(October (41)):7041-7046.
28. Morgeaux S., Milne C., Daas A. Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. Pharmeuropa Bio 2005, 2005(September (1)):19-26.
29. Yang C., Shi H., Zhou J., Liang Y., Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 2009, 27(August):6558-6563.